Opendata, web and dolomites

EYEGET SIGNED

Gene therapy of inherited retinal diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EYEGET project word cloud

Explore the words cloud of the EYEGET project. It provides you a very rough idea of what is the project "EYEGET" about.

progressive    millions    last    combination    capacity    reassemble    group    parallel    editing    initial    adeno    phenotyping    vector    transduction    content    drugs    mutations    retinal    therapeutic    toxic    vivo    photoreceptors    dominant    larger    vectors    worldwide    of    technologies    induction    witness    decade    expansion    gain    contributed    innovative    safe    vitro    cells    irds    screening    complementary    multiple    frequent    degenerations    function    quality    eye    clearance    co    gene    proof    inherited    reconstitute    limited    activation    autophagy    cargo    inexorable    genome    genes    pr    transplanted    rp    successes    option    eyeget    vision    cell    longer    mediated    overcome    blindness    strategies    efficient    administration    life    cure    whom    scenario    aavs    humans    significantly    expand    therapy    people    retinas    obtain    patients    viral    aav    lysosomal    convert    ird    methodology    limitations    fibroblasts   

Project "EYEGET" data sheet

The following table provides information about the project.

Coordinator
FONDAZIONE TELETHON 

Organization address
address: VIA VARESE 16/B
city: ROMA
postcode: 185
website: www.telethon.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 2˙499˙564 €
 EC max contribution 2˙499˙564 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-AdG
 Funding Scheme ERC-ADG
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FONDAZIONE TELETHON IT (ROMA) coordinator 2˙499˙564.00

Map

 Project objective

Inherited retinal degenerations (IRDs) are a major cause of blindness worldwide. IRD patients witness inexorable progressive vision loss as no therapy is currently available. In the last decade my group has significantly contributed to a change of this scenario by developing efficient adeno-associated viral (AAV) vectors for retinal gene therapy that are safe and effective in humans. The objective of EYEGET (EYE GEne Therapy) is to overcome some of the current major limitations in the field of retinal gene therapy to expand initial therapeutic successes to a larger number of IRDs. To achieve this, we propose to use four parallel, highly innovative and complementary approaches: i. expansion of the limited AAV cargo capacity by a novel methodology based on co-administration of multiple AAVs that reassemble in target retinal cells and reconstitute large genes; ii. targeting of frequent dominant gain-of-function mutations that cause RP using state-of-the-art AAV-mediated genome editing technologies; iii. induction of retinal cells clearance of toxic IRD products by AAV-mediated activation of autophagy and lysosomal function; iv. development of methodologies to directly convert fibroblasts to photoreceptors that can be transplanted in retinas from IRD patients with advanced PR loss and for whom in vivo gene therapy is no longer an option. We will use a combination of in vitro and in vivo state-of-the-art technologies including novel AAV vector design, high content screening of drugs that enhance AAV transduction, genome editing, and advanced in vivo retinal phenotyping to obtain proof-of-concept for each of these therapeutic strategies. The results from this study may impact the quality of life of millions of people worldwide by providing a cure based on gene and/or cell therapy for a large group of IRDs.

 Publications

year authors and title journal last update
List of publications.
2018 Ivana Trapani, Alberto Auricchio
Seeing the Light after 25 Years of Retinal Gene Therapy
published pages: 669-681, ISSN: 1471-4914, DOI: 10.1016/j.molmed.2018.06.006
Trends in Molecular Medicine 24/8 2019-04-02
2018 Andrea Maddalena, Fabio Dell\'Aquila, Pia Giovannelli, Paola Tiberi, Luca Giorgio Wanderlingh, Sandro Montefusco, Patrizia Tornabene, Carolina Iodice, Feliciano Visconte, Annamaria Carissimo, Diego Luis Medina, Gabriella Castoria, Alberto Auricchio
High-Throughput Screening Identifies Kinase Inhibitors That Increase Dual Adeno-Associated Viral Vector Transduction In Vitro and in Mouse Retina
published pages: 886-901, ISSN: 1043-0342, DOI: 10.1089/hum.2017.220
Human Gene Therapy 29/8 2019-09-05
2019 Ivana Trapani, Alberto Auricchio
Has retinal gene therapy come of age? From bench to bedside and back to bench
published pages: , ISSN: 0964-6906, DOI: 10.1093/hmg/ddz130
Human Molecular Genetics 2019-09-05
2018 Andrea Maddalena, Patrizia Tornabene, Paola Tiberi, Renato Minopoli, Anna Manfredi, Margherita Mutarelli, Settimio Rossi, Francesca Simonelli, Jurgen K. Naggert, Davide Cacchiarelli, Alberto Auricchio
Triple Vectors Expand AAV Transfer Capacity in the Retina
published pages: 524-541, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2017.11.019
Molecular Therapy 26/2 2019-09-05

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EYEGET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EYEGET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More  

HEIST (2020)

High-temperature Electrochemical Impedance Spectroscopy Transmission electron microscopy on energy materials

Read More